Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.
A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment. However, laparotomy revealed extensive adhesive fibrosis but no sign of malignant mesothelioma. The peritoneal complications of intraperitoneal cytostatic treatment are discussed.
Vlasveld
L T
LT
Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Amsterdam.
Taal
B G
BG
Kroon
B B
BB
Gallee
M P
MP
Rodenhuis
S
S
D000328:Adult; D001706:Biopsy; D005355:Fibrosis / Q000150:complications / Q000473:pathology; D006801:Humans; D007274:Injections, Intraperitoneal; D007415:Intestinal Obstruction / Q000209:etiology* / Q000473:pathology; D007579:Jejunal Diseases / Q000209:etiology* / Q000473:pathology; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000473:pathology; D008942:Mitoxantrone / Q000008:administration & dosage*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010537:Peritoneum / Q000473:pathology*; D012074:Remission Induction; D013997:Time Factors; D000267:Tissue Adhesions / Q000209:etiology / Q000473:pathology
D008942:Mitoxantrone